Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.
Starling Oncology
Latest Content
For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.
Treatment with the investigational Bruton’s tyrosine kinase inhibitor, pirtobrutinib, will be compared with ibrutinib treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in a phase 2 study.
A publicly traded leader in value-based oncology care raises standards in patient safety.
An executive announcement from the Oncology of Hope and Innovation Institute.
Two new TOI-affiliated oncology practices have open in South Florida.
The Oncology InstituteeExpands board to 9 members with deep healthcare management and investment experience.
The Oncology Institute, Inc ave partnered to provide enhanced psychological support services for TOI patients.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
A Look Inside CONVERGE: Intratumoral Therapy Comes to Locally Advanced NSCLC
2
DiBardino Outlines Phase 2 CONVERGE Trial Design of Radioenhancer in NSCLC
3
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up
5